Johan Sandin
Gründer bei ALZECURE PHARMA AB
Ursprung des Netzwerks ersten Grades von Johan Sandin
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 15 | |
Arguseye AB
 Arguseye AB Electronic Equipment/InstrumentsElectronic Technology Arguseye AB specializes in downstream bioprocessing and offers a stand-alone sensor system called ArgusOne that improves chromatography with real-time, in-line data. Arguseye is based in Linköping, SE and was founded by Ingemar Lundström, Johan Sandin, Erik Martinsson, and Daniel Aili. The Swedish company also provides innovative sensor solutions for real-time monitoring and control of biological systems and processes. Erik Martinsson has been the CEO since incorporation.
3
| Holding Company | Electronic Equipment/Instruments | 3 |
Sinfonia Biotherapeutics AB
 Sinfonia Biotherapeutics AB BiotechnologyHealth Technology Sinfonia Biotherapeutics AB is a Swedish clinical stage company that develops biologics for neuropathic pain. The private company is based in Huddinge, Sweden.
2
| Private Company | Biotechnology | 2 |
Ac Intressenter AB
1
| Private Company | 1 | |
Alzecure Discovery AB
1
| Private Company | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Johan Sandin
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| ABLIVA AB | Pharmaceuticals: Major | Chief Executive Officer | |
| BIOINVENT INTERNATIONAL AB | Biotechnology | Director/Board Member | |
| MEDIVIR AB | Pharmaceuticals: Major | Director/Board Member | |
| Karolinska Institutet | College/University | Doctorate Degree Corporate Officer/Principal | |
| University of Uppsala | College/University | Doctorate Degree Doctorate Degree Graduate Degree | |
Agendia NV
 Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Medical/Nursing Services | Director/Board Member | |
| University of Stockholm | College/University | Graduate Degree | |
| PLUS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Royal Institute of Technology | College/University | Graduate Degree | |
| Erasmus University Rotterdam | College/University | Doctorate Degree | |
| University of Leiden | College/University | Doctorate Degree | |
| PHARMACOLOG I UPPSALA AB | Electronic Equipment/Instruments | Director/Board Member | |
Agendia, Inc.
 Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Pharmaceuticals: Major | Director/Board Member | |
Apotek Produktion & Laboratorier AB
 Apotek Produktion & Laboratorier AB Pharmaceuticals: MajorHealth Technology Apotek Produktion & Laboratorier AB develops and manufactures pharmaceutical products. Its services include analytical services, clinical trials and contract manufacturing. The company is headquartered in Kungens Kurva, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
Amgen AB
 Amgen AB BiotechnologyHealth Technology Amgen AB conducts biotechnology research and experimental development. It focuses on the following therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation. The company was founded in 1980 and is headquartered in Solna, Sweden. | Biotechnology | Chief Executive Officer | |
| ASARINA PHARMA AB | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Corporate Officer/Principal | |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Medical/Nursing Services | Director/Board Member | |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| MODUS THERAPEUTICS HOLDING AB | Biotechnology | Director/Board Member | |
| Yale School of Medicine | College/University | Doctorate Degree | |
| GABATHER AB | Pharmaceuticals: Major | Director of Finance/CFO | |
| Stockholm Business School | College/University | Masters Business Admin | |
| Hult International Business School | College/University | Masters Business Admin | |
| IRLAB THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member | |
| Stockholm Brain Institute | Chairman | ||
| SAVARA INC. | Pharmaceuticals: Major | Director/Board Member | |
Mireca Medicines GmbH
 Mireca Medicines GmbH Pharmaceuticals: MajorHealth Technology Mireca Medicines GmbH develops treatment for hereditary eye disease. The company was founded by François Paquet-Durand, Pieter Jaap Gaillard and Barbara Brunnhuber in 2017 and is headquartered in Tubingen, | Pharmaceuticals: Major | Director/Board Member | |
Valneva Sweden AB
 Valneva Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers. | Biotechnology | Chief Executive Officer | |
Lobsor Pharmaceuticals AB
 Lobsor Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of Nidda Topco SARL, Lobsor Pharmaceuticals AB is a Swedish company that manufactures and wholesales pharmaceutical products. The company is based in Uppsala, Sweden. The company was founded by Ulf Rosén, who has been the CEO since incorporation. Lobsor Pharmaceuticals was acquired by STADA Arzneimittel AG, a subsidiary of Nidda Topco SARL from LobSor Holding AB on October 02, 2020. | Pharmaceuticals: Major | Chairman | |
| Christian Storck Management AB | Corporate Officer/Principal | ||
Juvenescence Ltd.
 Juvenescence Ltd. Financial ConglomeratesFinance Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom. | Financial Conglomerates | Corporate Officer/Principal | |
Kapitel Tre AB
 Kapitel Tre AB Miscellaneous Commercial ServicesCommercial Services Kapitel Tre AB provides business and management consulting services. The private company is located in Sweden. | Miscellaneous Commercial Services | Chief Executive Officer | |
| van Es Consulting AB | Director/Board Member | ||
| R Linder Holding AB | Director/Board Member | ||
| Enable-Finance & Business Development AB | Chief Executive Officer | ||
Favro AB
 Favro AB Information Technology ServicesTechnology Services Favro AB engages in the provision of a planning and collaboration application for organizational flow. It focuses on helping developers, marketers, and executives. The company was founded by Hans Dahlström, Erik Olofsson, and Patric Palm in 2016 and is headquartered in Uppsala, Sweden. | Information Technology Services | Chief Executive Officer | |
| Favro North America, Inc. | Corporate Secretary | ||
| Helander & Lundvik Ekonomikonsulter AB | Corporate Officer/Principal | ||
| ECTIN RESEARCH AB | Biotechnology | Director of Finance/CFO | |
| LUMOS PHARMA, INC. | Pharmaceuticals: Major | Director/Board Member | |
| 3D Trace AB | Director/Board Member | ||
NorthX Biologics Matfors AB
 NorthX Biologics Matfors AB BiotechnologyHealth Technology NorthX Biologics Matfors AB is a biologics company that specializes in high-quality protein production and DNA manufacturing. The company is based in Matfors, Sweden, and has subsidiaries in Sweden. The Swedish company offers comprehensive cell banking services, including master cell bank production, GMP cell banking, and cell bank characterization, ensuring quality and compliance for biological products. The company also provides premium plasmid DNA services, offering GMP, High Quality, and Research Grade plasmids for gene therapy, cell therapy, molecular biology research, and clinical applications. The company was founded in 1963, and Janet Hoogstraate has been the CEO of the company since 2023. | Biotechnology | Chief Executive Officer | |
Melius Pharma AB
 Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | Pharmaceuticals: Major | Director of Finance/CFO | |
| Tegnér Biotech Consulting AB | Director/Board Member | ||
| Hoogstraate Consulting AB. | Chief Executive Officer | ||
| The Dutch Chamber of Commerce In Sweden | Director/Board Member | ||
| SENSIDOSE AB | Electronic Equipment/Instruments | Director of Finance/CFO | |
| BIOEXTRAX AB | Biotechnology | Director of Finance/CFO |
Statistik
International
| Schweden | 37 |
| Vereinigte Staaten | 8 |
| Niederlande | 4 |
| Deutschland | 3 |
| Vereinigte Arabische Emirate | 2 |
Sektoral
| Health Technology | 23 |
| Consumer Services | 10 |
| Commercial Services | 3 |
| Health Services | 3 |
| Electronic Technology | 3 |
Operativ
| Director/Board Member | 66 |
| Corporate Officer/Principal | 23 |
| Chief Executive Officer | 22 |
| Chairman | 17 |
| Founder | 12 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Johan Sandin
- Unternehmensverbindungen